bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Methods and Materials and Supplementary Figures 1-2 from Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Authors: LoRusso Patricia , Jänne Pasi A. , Oliveira Moacyr , Rizvi Naiyer , Malburg Lisa , Keedy Vicki , Yee Lorrin , Copigneaux Catherine , Hettmann Thore , Wu Chi-Yuan , Ang Agnes , Halim Abdel-Baset , Beckman Robert A. , Beaupre Darrin , Berlin Jordan
Published: April 2023

PDF - 278K, Supplementary Methods and Materials, QTc prolongation results. Supplementary Figure 1 - QTc prolongation compared with serum U3-1287 concentration. Supplementary Figure 2 - U3-1287-mediated pancreatic xenograft growth inhibition)
Supplementary Methods from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
Authors: Kurzrock Razelle , Voorhees Peter M. , Casper Corey , Furman Richard R. , Fayad Luis , Lonial Sagar , Borghaei Hossein , Jagannath Sundar , Sokol Lubomir , Usmani Saad Z. , van de Velde Helgi , Qin Xiang , Puchalski Thomas A. , Hall Brett , Reddy Manjula , Qi Ming , van Rhee Frits
Published: April 2023

Supplementary Methods - PDF file 88K, Supplementary methods for pharmacokinetic analyses and pharmacodynamic analyses
Supplementary Figure 1 from Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses
Authors: Coughlin Kathleen , Anchoori Ravi , Iizuka Yoshie , Meints Joyce , MacNeill Lauren , Vogel Rachel Isaksson , Orlowski Robert Z. , Lee Michael K. , Roden Richard B.S. , Bazzaro Martina
Published: April 2023

PDF file - 722KB, Dose- and time-dependent accumulation of poly-ubiquitinated proteins following RA-9 exposure.
Supplementary Table 1 from Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
Authors: Rosenblatt Jacalyn , Avivi Irit , Vasir Baldev , Uhl Lynne , Munshi Nikhil C. , Katz Tami , Dey Bimalangshu R. , Somaiya Poorvi , Mills Heidi , Campigotto Federico , Weller Edie , Joyce Robin , Levine James D. , Tzachanis Dimitrios , Richardson Paul , Laubach Jacob , Raje Noopur , Boussiotis Vassiliki , Yuan Yan Emily , Bisharat Lina , Held Viki , Rowe Jacob , Anderson Kenneth , Kufe Donald , Avigan David
Published: April 2023

PDF file - 1227K, Vaccine Characterization.
Supplementary Figure Legend from The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
Authors: Wang Rui , Pan Yunjian , Li Chenguang , Hu Haichuan , Zhang Yang , Li Hang , Luo Xiaoyang , Zhang Jie , Fang Zhaoyuan , Li Yuan , Shen Lei , Ji Hongbin , Garfield David , Sun Yihua , Chen Haiquan
Published: April 2023

PDF file, 49K.
Supplementary Figures 1-5 from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
Authors: Yen Wan-Ching , Fischer Marcus M. , Hynes Mark , Wu Jingjiang , Kim Edward , Beviglia Lucia , Yeung V. Pete , Song Xiaomei , Kapoun Ann M. , Lewicki John , Gurney Austin , Simeone Diane M. , Hoey Timothy
Published: April 2023

PDF file - 139K, Figure S1. DLL4 expression in pancreatic tumor xenografts relative to normal human pancreas. Figure S2. Effect of anti-DLL4 on growth of orthotoptically implanted pancreatic xenograft tumors. Figure S3. Individual tumor measurements for In Vivo Limiting Dilution Assay. Figure S4. Effect of anti-hDLL4, anti-mDLL4, anti-DLL4 and gemcitabine on EMT marker expression
Supplementary Figure legends from The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
Authors: Godbersen J. Claire , Humphries Leigh Ann , Danilova Olga V. , Kebbekus Peter E. , Brown Jennifer R. , Eastman Alan , Danilov Alexey V.
Published: April 2023

Supplementary Figure legends
Supplementary Figure 6 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
Authors: Godbersen J. Claire , Humphries Leigh Ann , Danilova Olga V. , Kebbekus Peter E. , Brown Jennifer R. , Eastman Alan , Danilov Alexey V.
Published: April 2023

PDF file - 174KB, siRNA-mediated knockdown of Noxa and Puma results in a decrease in corresponding transcript levels. CLL cells (N=4) were transfected with two individual siRNA's against Noxa, a Puma-targeting siRNA or control siRNA using Amaxa program X-05. Immediately after nucleofection, cells were cultured on CD40L-expressing stroma for 24 hours, followed by incubation with MLN4924 or vehicle control. (A) Apoptosis within CD19+ subset of cells was determined by Annexin V and 7-AAD staining after 48 hours with MLN4924. (B) Total RNA was isolated from CLL B-cells after 24 hours incubation with MLN4924, reverse-transcribed and subjected to real-time PCR with the indicated probes (in duplicates). Results were normalized to 18S levels. Fold induction of the corresponding mRNA compared to control siRNA-transfected samples is shown. Data are the mean � SE. * - p<0.05.
Supplementary Figure 6 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
Authors: Godbersen J. Claire , Humphries Leigh Ann , Danilova Olga V. , Kebbekus Peter E. , Brown Jennifer R. , Eastman Alan , Danilov Alexey V.
Published: April 2023

siRNA-mediated knockdown of Noxa and Puma results in a decrease in corresponding transcript levels. CLL cells (N=4) were transfected with two individual siRNA's against Noxa, a Puma-targeting siRNA or control siRNA using Amaxa program X-05. Immediately after nucleofection, cells were cultured on CD40L-expressing stroma for 24 hours, followed by incubation with MLN4924 or vehicle control. (A) Apoptosis within CD19+ subset of cells was determined by Annexin V and 7-AAD staining after 48 hours with MLN4924. (B) Total RNA was isolated from CLL B-cells after 24 hours incubation with MLN4924, reverse-transcribed and subjected to real-time PCR with the indicated probes (in duplicates). Results were normalized to 18S levels. Fold induction of the corresponding mRNA compared to control siRNA-transfected samples is shown. Data are the mean {plus minus} SE. * - p<0.05
Supplementary Figure 4 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
Authors: Godbersen J. Claire , Humphries Leigh Ann , Danilova Olga V. , Kebbekus Peter E. , Brown Jennifer R. , Eastman Alan , Danilov Alexey V.
Published: April 2023

PDF file - 74KB, MLN4924 leads to downregulation of NFkappaB activity in a dose-dependent manner. (A) MLN4924 leads to downregulation of CXCR5 in CLL. CLL cells (N=9) were co-cultured with CD40L-expressing stroma for 24 hours, followed by incubation with 1 microM MLN4924 or vehicle control for 24 h. Total RNA was isolated from CD19+ CLL B-cells, reverse-transcribed and subjected to real-time PCR with the indicated probes (in duplicates). Results were normalized to 18S levels. (B-C) CLL cells (N=4) were co-cultured with CD40L-expressing stroma for 24 hours, followed by incubation with 0.25 or 1 microM MLN4924 or vehicle control for another 24 h. Nuclear protein fractions were isolated and p50 and p65 activity was measured by ELISA as per manufacturer's instructions (B). Total RNA was reverse-transcribed (C) and subjected to real-time PCR with the indicated probes (in duplicates). Results were normalized to 18S levels. Measurements were normalized to vehicle control and reported as a fold change. * - p<0.05 and ** - p<0.01 compared to untreated control.
Supplemental Methods, Figure 1,Tables 1-6 from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Authors: Bowles Daniel W. , Diamond Jennifer R. , Lam Elaine T. , Weekes Colin D. , Astling David P. , Anderson Ryan T. , Leong Stephen , Gore Lia , Varella-Garcia Marileila , Vogler Brian W. , Keysar Stephen B. , Freas Elizabeth , Aisner Dara L. , Ren Chen , Tan Aik-Chook , Wilhelm Francois , Maniar Manoj , Eckhardt S. Gail , Messersmith Wells A. , Jimeno Antonio
Published: April 2023

Supplemental Figure S1: Supplemental Figure 1 shows the pharmacokinetic plasma concentration curve following a single dose of oral rigosertib, revealing dose-dependent pharmacokinetics; Supplemental Table S1: This file provides individual patient characteristics, including demographics, time on study, best response, and duration of response; Supplemental Table S2: Adverse events, including the result of the adverse event (drug holding or dose reduction) are described for each patient; Supplemental Table S3: All serious adverse events are described in this file according to patient identification number, as is the relationship to rigosertib; Supplemental Table S4: This file gives the detailed results of multiplex mutation testing for each patient enrolled in this study whose tumor was analyzed; Supplemental Table S5: Validated exome sequencing results for patients with sensitive and resistant squamous cell carcinomas are described, including gene, position, and nucleotide affected; Supplemental Table S6: This file shows the exome sequencing coverage for each assessed squamous cell carcinoma.
Supplementary Figure 1 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
Authors: Godbersen J. Claire , Humphries Leigh Ann , Danilova Olga V. , Kebbekus Peter E. , Brown Jennifer R. , Eastman Alan , Danilov Alexey V.
Published: April 2023

PDF file - 69KB, MLN4924-induces apoptosis of the CLL B-cells on CD40L-expressing stroma is independent of IGHV mutational status (A) and cytogenetics (B, C). CLL cells were cultured on CD40L-expressing stroma for 24 hours, followed by incubation with 1 μM MLN4924 or vehicle control for 48 hours. Apoptosis within CD19+ subset of cells was determined by Annexin V and 7-AAD staining and normalized to the time-matched untreated controls. Horizontal lines represent the mean. (C) % apoptosis plotted against the size of a 17p deletion clone in 11 individual CLL samples (r=-0.2, p=0.56).
Supplementary Figure 1 from Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
Authors: Leone Emanuela , Morelli Eugenio , Di Martino Maria T. , Amodio Nicola , Foresta Umberto , Gullà Annamaria , Rossi Marco , Neri Antonino , Giordano Antonio , Munshi Nikhil C. , Anderson Kenneth C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

PDF file - 395K, Figure S1. Flow cytometric analysis of CD38+ MM cells separated by immunomagnetic beads from co-cultured INA-6 (A) and ppMM (B) cells with BMSCs from representative samples.
Supplementary Tables 1 - 8 from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
Authors: Bastian Lorenz , Hof Jana , Pfau Madlen , Fichtner Iduna , Eckert Cornelia , Henze Günter , Prada Javier , von Stackelberg Arend , Seeger Karl , Shalapour Shabnam
Published: April 2023

PDF file - 277K, S1: Fractional Product of Webb calculations for concomitant VPA/BTZ treatment in Nalm6; S2: Ic25 and Ic50 values for HDACis; S3: Fractional Product of Webb calculations for concomitant VPA/BTZ treatment in 697, SD-1 and SEM cells and S4: for sequential combinations; S5: NF-kappaB subunits gene expression analyses in primary LC in correlation with the clinical characteristics of the BCP-ALL relapse patient cohort; S6: Mortality in the s.c.- and i.v.- xenograft mouse models; S7: Microarray analysis of the upregulated genes in Reh cells after VPA/BTZ treatment and S8: of the downregulated genes.
Supplementary Table 3 from Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization
Authors: Niesvizky Ruben , Mark Tomer M. , Ward Maureen , Jayabalan David S. , Pearse Roger N. , Manco Megan , Stern Jessica , Christos Paul J. , Mathews Lena , Shore Tsiporah B. , Zafar Faiza , Pekle Karen , Xiang Zhaoying , Ely Scott , Skerret Donna , Chen-Kiang Selina , Coleman Morton , Lane Maureen E.
Published: April 2023

PDF file - 53K, Validation of gene expression data using QPCR compared to microarray values (data reported as fold change).
Supplementary Figure Legend from hTERT Inhibition Triggers Epstein–Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies
Authors: Giunco Silvia , Dolcetti Riccardo , Keppel Sonia , Celeghin Andrea , Indraccolo Stefano , Dal Col Jessica , Mastorci Katy , De Rossi Anita
Published: April 2023

PDF file - 85K
Supplementary Figure 2 from hTERT Inhibition Triggers Epstein–Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies
Authors: Giunco Silvia , Dolcetti Riccardo , Keppel Sonia , Celeghin Andrea , Indraccolo Stefano , Dal Col Jessica , Mastorci Katy , De Rossi Anita
Published: April 2023

PDF file - 130K, Effects of shRNA hTERT and ganciclovir on cell cycle and cell viability in Raji and HBL-1 cell lines.
Supplementary Figure 3 from Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics
Authors: Stacchiotti S. , Tortoreto M. , Bozzi F. , Tamborini E. , Morosi C. , Messina A. , Libertini M. , Palassini E. , Cominetti D. , Negri T. , Gronchi A. , Pilotti S. , Zaffaroni N. , Casali P.G.
Published: April 2023

PDF file, 110K, The xenografts were sacrificed five days after starting sunitinib, bevacizumab and pazopanib. One sample was obtained also 4 weeks after the end of treatment with pazopanib. PDGFRB and VEGFR2 activation was analyzed trough immunoprecipitation (IP) and western blotting (WB). PDGFRB activation was reduced by sunitinib and pazopanib, while VEGFR2 activation was decreased by bevacizumab and pazopanib. A re-activation of both PDGFRB and VEGFR2 was detected after 4 weeks of treatment with pazopanib.
Supplementary figure 1 from Altered DNA Methylation Landscapes of Polycomb-Repressed Loci Are Associated with Prostate Cancer Progression and ERG Oncogene Expression in Prostate Cancer
Authors: Kron Ken , Trudel Dominique , Pethe Vaijayanti , Briollais Laurent , Fleshner Neil , van der Kwast Theodorus , Bapat Bharati
Published: April 2023

Supplementary figure 1 PDF file 3484K, Methodological flow-chart; summary of methodology used to select specimens for methylation profiling and ERG expression
Supplementary Figure 1 from Profiling Three-Dimensional Nuclear Telomeric Architecture of Myelodysplastic Syndromes and Acute Myeloid Leukemia Defines Patient Subgroups
Authors: Gadji Macoura , Adebayo Awe Julius , Rodrigues Prerana , Kumar Rajat , Houston Donald S. , Klewes Ludger , Dièye Tandakha Ndiaye , Rego Eduardo Magalhães , Passetto Roberto Falcão , de Oliveira Fábio Morato , Mai Sabine
Published: April 2023

PDF file, 203KB, Different subgroups according to 3D telomeric profiles and their proposed chronological evolution. Their different 3D telomere intensities are shown as: (Red bars) show the different cell populations as in figure 1C; (Red arrows) indicate the direction of telomere variations; (Black arrows) indicate the direction of progression from one subgroup to the other. All MDS patients were classified in subgroups with graphs (A to F, and I to K). However, AML patients were classified in subgroups with graphs (G, H, L to O).
Supplementary Figure 1 from Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Authors: Chandarlapaty Sarat , Sakr Rita A. , Giri Dilip , Patil Sujata , Heguy Adriana , Morrow Monica , Modi Shanu , Norton Larry , Rosen Neal , Hudis Clifford , King Tari A.
Published: April 2023

PDF file - 38K, Data flow diagram of the secondary/progressive lesions
Supplementary Figure 3 from DNA Topoisomerase III Alpha Regulates p53-Mediated Tumor Suppression
Authors: Hsieh Mei-Yi , Fan Jia-Rong , Chang Han-Wen , Chen Hsiang-Chin , Shen Tang-Long , Teng Shu-Chun , Yeh Yen-Hsiu , Li Tsai-Kun
Published: April 2023

PDF file 1548KB, hTOP3alpha regulates TP53 mRNA and p53 protein stability
Supplementary Figure 2 from DNA Topoisomerase III Alpha Regulates p53-Mediated Tumor Suppression
Authors: Hsieh Mei-Yi , Fan Jia-Rong , Chang Han-Wen , Chen Hsiang-Chin , Shen Tang-Long , Teng Shu-Chun , Yeh Yen-Hsiu , Li Tsai-Kun
Published: April 2023

PDF file 1796K, Forced expression of hTOP3alpha induced expression of p5315P, p21 and {gamma}H2AX, but not ATM1981P under DNA damaging-agent stimulation
Supplementary Materials from Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer
Authors: Wrangle John , Machida Emi Ota , Danilova Ludmila , Hulbert Alicia , Franco Noreli , Zhang Wei , Glöckner Sabine C. , Tessema Mathewos , Van Neste Leander , Easwaran Hariharan , Schuebel Kornel E. , Licchesi Julien , Hooker Craig M. , Ahuja Nita , Amano Jun , Belinsky Steven A. , Baylin Stephen B. , Herman James G. , Brock Malcolm V.
Published: April 2023

PDF file - 108KB
Supplementary Figure 4 from Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer
Authors: Wrangle John , Machida Emi Ota , Danilova Ludmila , Hulbert Alicia , Franco Noreli , Zhang Wei , Glöckner Sabine C. , Tessema Mathewos , Van Neste Leander , Easwaran Hariharan , Schuebel Kornel E. , Licchesi Julien , Hooker Craig M. , Ahuja Nita , Amano Jun , Belinsky Steven A. , Baylin Stephen B. , Herman James G. , Brock Malcolm V.
Published: April 2023

PDF file - 399KB, Kaplan-Meier Survival Curves for Non-Small Cell Lung Cancer for p16 methylation in combination with APC, RASSF1, or CDH13.
Supplementary Figure 3 from Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer
Authors: Wrangle John , Machida Emi Ota , Danilova Ludmila , Hulbert Alicia , Franco Noreli , Zhang Wei , Glöckner Sabine C. , Tessema Mathewos , Van Neste Leander , Easwaran Hariharan , Schuebel Kornel E. , Licchesi Julien , Hooker Craig M. , Ahuja Nita , Amano Jun , Belinsky Steven A. , Baylin Stephen B. , Herman James G. , Brock Malcolm V.
Published: April 2023

PDF file - 287KB, DNA Methylation of CDO1, HOXA9, and TAC1 is Highly Sensitive for Stage I NSCLC in the Cancer Genome Atlas.
Supplementary Figure 2 from Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer
Authors: Wrangle John , Machida Emi Ota , Danilova Ludmila , Hulbert Alicia , Franco Noreli , Zhang Wei , Glöckner Sabine C. , Tessema Mathewos , Van Neste Leander , Easwaran Hariharan , Schuebel Kornel E. , Licchesi Julien , Hooker Craig M. , Ahuja Nita , Amano Jun , Belinsky Steven A. , Baylin Stephen B. , Herman James G. , Brock Malcolm V.
Published: April 2023

PDF file - 100KB, DNA Methylation of CDO1, HOXA9, and TAC1 is Highly Sensitive for Stage I NSCLC in the Cancer Genome Atlas.
Supplementary Table 1 from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
Authors: Cohen Ezra E.W. , Wu Kehua , Hartford Christine , Kocherginsky Masha , Eaton Kimberly Napoli , Zha Yuanyuan , Nallari Anitha , Maitland Michael L. , Fox-Kay Kammi , Moshier Kristin , House Larry , Ramirez Jacqueline , Undevia Samir D. , Fleming Gini F. , Gajewski Thomas F. , Ratain Mark J.
Published: April 2023

PDF file - 63K, Dosing Summary of Sirolimus Phase I Studies
Supplementary Table S5 from Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer
Authors: Zhang Geng , He Peijun , Tan Hanson , Budhu Anuradha , Gaedcke Jochen , Ghadimi B. Michael , Ried Thomas , Yfantis Harris G. , Lee Dong H. , Maitra Anirban , Hanna Nader , Alexander H. Richard , Hussain S. Perwez
Published: April 2023

Supplementary Table S5 - PDF file 71K, Gene expression profiles of PNLIP, CLPS, PNLIPRP1 and PNLIPRP2 in PDAC in the Oncomine database
Supplementary Table S4 from Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer
Authors: Zhang Geng , He Peijun , Tan Hanson , Budhu Anuradha , Gaedcke Jochen , Ghadimi B. Michael , Ried Thomas , Yfantis Harris G. , Lee Dong H. , Maitra Anirban , Hanna Nader , Alexander H. Richard , Hussain S. Perwez
Published: April 2023

Supplementary Table S4 - PDF file 71K, 157 gene surrogates of 8 fatty acids are differentially expressed between tumor and nontumor tissues in PDAC cases
Supplementary Table S3 from Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer
Authors: Zhang Geng , He Peijun , Tan Hanson , Budhu Anuradha , Gaedcke Jochen , Ghadimi B. Michael , Ried Thomas , Yfantis Harris G. , Lee Dong H. , Maitra Anirban , Hanna Nader , Alexander H. Richard , Hussain S. Perwez
Published: April 2023

Supplementary Table S3 - PDF file 53K, Metabolites in the turquoise module identified using WGCNA
Supplementary Fig. S4 from A Short Treatment with Galactomannan GM-CT-01 Corrects the Functions of Freshly Isolated Human Tumor–Infiltrating Lymphocytes
Authors: Demotte Nathalie , Bigirimana René , Wieërs Grégoire , Stroobant Vincent , Squifflet Jean-Luc , Carrasco Javier , Thielemans Kris , Baurain Jean-François , Van Der Smissen Patrick , Courtoy Pierre J. , van der Bruggen Pierre
Published: April 2023

PDF file 156K, Efficacy of different galactomannans for boosting TIL functions
Related Article from MicroRNA Dissects Out Dangerous Pancreatic Cysts from All the Rest
Authors: Thomas Ryan M. , Fleming Jason B.
Published: April 2023

Related Article from MicroRNA Dissects Out Dangerous Pancreatic Cysts from All the Rest
Supplementary Tables 1 - 3 from Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study
Authors: Gajjar Amar , Stewart Clinton F. , Ellison David W. , Kaste Sue , Kun Larry E. , Packer Roger J. , Goldman Stewart , Chintagumpala Murali , Wallace Dana , Takebe Naoko , Boyett James M. , Gilbertson Richard J. , Curran Tom
Published: April 2023

PDF file - 104K, Supplementary Table S1. Vismodegib Dosing Strategy Supplementary Table S2. Commonly Reported Adverse Events According to Grade Supplementary Table S3. Pharmacokinetics of Unbound Vismodegib in Pediatric Patients with Medulloblastoma
Supplementary Figures 1 - 2 from Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study
Authors: Gajjar Amar , Stewart Clinton F. , Ellison David W. , Kaste Sue , Kun Larry E. , Packer Roger J. , Goldman Stewart , Chintagumpala Murali , Wallace Dana , Takebe Naoko , Boyett James M. , Gilbertson Richard J. , Curran Tom
Published: April 2023

PDF file - 156K, Supplementary Fig. S1. Concentration-time plots of the first 72 hours after administration of the first vismodegib dose during Course 1 to the patients in the initial cohort: 6 received 85 mg/m2 (Figure A & B), and 7 received 170 mg/m2 (Figure C &D). Plasma concentrations of total vismodegib (A, C) and unbound vismodegib (B, D) were measured. Supplementary Fig S2. The relation between total vismodegib plasma concentrations and alpha-1-acid glycoprotein (AAGP) plasma concentrations in pediatric patients. The scatter plot includes all data from patients treated in this study. The solid line represents the best-fit line from linear regression analysis (R2= 0.38).
Supplementary Methods from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
Authors: Singh Jagdeep K. , Farnie Gillian , Bundred Nigel J. , Simões Bruno M , Shergill Amrita , Landberg Göran , Howell Sacha J. , Clarke Robert B.
Published: April 2023

PDF file - 66K
Supplementary Figure Legend from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
Authors: Singh Jagdeep K. , Farnie Gillian , Bundred Nigel J. , Simões Bruno M , Shergill Amrita , Landberg Göran , Howell Sacha J. , Clarke Robert B.
Published: April 2023

PDF file - 79K
Supplementary Materials and Methods from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
Authors: Veomett Nicholas , Dao Tao , Liu Hong , Xiang Jingyi , Pankov Dmitry , Dubrovsky Leonid , Whitten Joseph A. , Park Sun-Mi , Korontsvit Tatyana , Zakhaleva Victoria , Casey Emily , Curcio Michael , Kharas Michael G. , O'Reilly Richard J. , Liu Cheng , Scheinberg David A.
Published: April 2023

PDF file - 105KB
Supplementary Figure 4 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
Authors: Veomett Nicholas , Dao Tao , Liu Hong , Xiang Jingyi , Pankov Dmitry , Dubrovsky Leonid , Whitten Joseph A. , Park Sun-Mi , Korontsvit Tatyana , Zakhaleva Victoria , Casey Emily , Curcio Michael , Kharas Michael G. , O'Reilly Richard J. , Liu Cheng , Scheinberg David A.
Published: April 2023

PDF file - 145KB, All human antibodies tested accumulated more in spleens of HLA-A2+ transgenic mice, but ESK1 did not bind specifically to isolated HLA-A2+ spleen, bone marrow or thymus cells. (A) Accumulation of 125 I-labeled antibodies in spleens of C57BL6/J or HLA-A2+ transgenic mice relative to antibody level in the blood. Mice were injected retroorbitally with 2microg indicated antibody, then sacrificed after 24 hours for blood and spleen collection. (B) Specific binding of 125I-labeled ESK1 to bone marrow, spleen, or thymus cells isolated from C57BL6/J or HLA-A2+ transgenic mice. Tissues were collected from 2 (C57) or 3 (HLA-A2+ transgenic) mice, then bound by 1microg/mL 125 I-labeled ESK1 either alone or after blocking with 50-fold excess unlabeled ESK1. Specific binding was determined, and #ESK1 bound per cell was calculated.
Supplementary Table 5 from CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer
Authors: Cleven Arjen H.G. , Derks Sarah , Draht Muriel X.G. , Smits Kim M. , Melotte Veerle , Van Neste Leander , Tournier Benjamin , Jooste Valerie , Chapusot Caroline , Weijenberg Matty P. , Herman James G. , de Bruïne Adriaan P. , van Engeland Manon
Published: April 2023

Univariate HRs of 24 single genes overall and for the stage 2, MSS, BRAF-wild type subgroup and stage 3, MSS, BRAF-wild type subgroup within the study population.
Supplementary Figure 4 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Authors: Zimmerman Eric I. , Hu Shuiying , Roberts Justin L. , Gibson Alice A. , Orwick Shelley J. , Li Lie , Sparreboom Alex , Baker Sharyn D.
Published: April 2023

PDF file - 282K, Influence of Oatp1b2-deficiency on the metabolic ratio of sorafenib-glucuronide and sorafenib N-oxide in vivo.
Supplementary Figure 2 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Authors: Zimmerman Eric I. , Hu Shuiying , Roberts Justin L. , Gibson Alice A. , Orwick Shelley J. , Li Lie , Sparreboom Alex , Baker Sharyn D.
Published: April 2023

PDF file - 33K, Drug diffusion in PAMPA assay.
Supplementary Figure 2 from Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma
Authors: Kaneko Naoki , Mitsuoka Keisuke , Amino Nobuaki , Yamanaka Kentaro , Kita Aya , Mori Masamichi , Miyoshi Sosuke , Kuromitsu Sadao
Published: April 2023

PDF file - 131KB, 18F-FLT PET imaging in a SU-DHL-8 disseminated xenograft model.
Supplementary Figure 1 from Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma
Authors: Kaneko Naoki , Mitsuoka Keisuke , Amino Nobuaki , Yamanaka Kentaro , Kita Aya , Mori Masamichi , Miyoshi Sosuke , Kuromitsu Sadao
Published: April 2023

PDF file - 42KB, Expression of survivin in B-cell NHL cell lines.
Supplementary Tables 1 - 5 from miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts
Authors: Matthaei Hanno , Wylie Dennis , Lloyd Maura B. , Dal Molin Marco , Kemppainen Jon , Mayo Skye C. , Wolfgang Christopher L. , Schulick Richard D. , Langfield Laura , Andruss Bernard F. , Adai Alex T. , Hruban Ralph H. , Szafranska-Schwarzbach Anna E. , Maitra Anirban
Published: April 2023

XLS file, 48K, Supplemental Figure 1: (A) Laser microdissection in an IPMN (hematoxylin and eosin; original magnification: 10x); (B) After precise marking and microdissection the neoplastic epithelium is catapulted into a sterile tube for subsequent RNA extraction. (C) The section after dissection. Supplemental Figure 2: Detailed diagram of the study design, describing experimental setup of FFPE (FTS) and cyst fluid (CFS) studies, including number of specimens used and number of miRNA candidates identified in the course of each study. Supplemental Figure 3: Mean Cts for all FTS and CFS specimens. (A) Megaplex RT-qPCR data for FTS. (B) and (C) Singleplex RT-qPCR data for FTS. (D) Megaplex RT-qPCR data for CFS. (E) and (F) Singleplex RT-qPCR data for CFS. Supplemental Figure 4: Boxplots showing raw Ct values for Megaplex (A) and singleplex (B) RT-qPCR expression analyses of FTS1 and FTS1 plus FTS2, respectively. The diagnosis associated with each sample is indicated by color, while the FTS1 and FTS2 specimens are depicted as separate panels in the singleplex boxplot (B). Supplemental Figure 5: Boxplots showing raw Ct values for Megaplex (A) and singleplex (B) RT-qPCR expression analyses of cyst fluid specimens from the CFS1 and CFS1 plus CFS2, respectively. Diagnosis is indicated by color, the CFS1 and CFS2 specimens by panel. Supplemental Figure 6: Boxplots of raw Ct values for singleplex RT-qPCR expression analysis of the CFS1 and CFS2 specimens with reassignment to test or training set indicated by separation of panels. Supplemental Figure 7: Raw Ct values of miRNAs involved in DiffPairs comprising the logistic regression model in the CFS1 and CFS2 specimens. Raw Ct for miR-21, which is not a part of the logistic regression model, are also shown. Supplemental Figure 8: PCA applied to raw Cts (A) and restricted mean-center normalized Cts. (B) CFS1 and CFS2 singleplex RT-qPCR data. Note that CFS1 and CFS2 specimens do not separate in either plot.
Supplementary Table 1 from CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids
Authors: Swarts Dorian R.A. , Henfling Mieke E.R. , Van Neste Leander , van Suylen Robert-Jan , Dingemans Anne-Marie C. , Dinjens Winand N.M. , Haesevoets Annick , Rudelius Martina , Thunnissen Erik , Volante Marco , Van Criekinge Wim , van Engeland Manon , Ramaekers Frans C.S. , Speel Ernst-Jan M.
Published: April 2023

XLSX file - 12K, Primer sequences
Supplementary Figure 2 from CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids
Authors: Swarts Dorian R.A. , Henfling Mieke E.R. , Van Neste Leander , van Suylen Robert-Jan , Dingemans Anne-Marie C. , Dinjens Winand N.M. , Haesevoets Annick , Rudelius Martina , Thunnissen Erik , Volante Marco , Van Criekinge Wim , van Engeland Manon , Ramaekers Frans C.S. , Speel Ernst-Jan M.
Published: April 2023

PDF file - 15946K, Representative immunohistochemical staining patterns for CD44 (A) and OTP (B-C), in (A) a large cell neuroendocrine carcinoma with absence of membranous CD44 staining in the tumor cells but presence of CD44 near necrotic areas and in inflammatory cells. (B) SCLC with moderate to strong nuclear OTP reactivity. This patient had no evidence of disease seven years after initial diagnosis, and was still alive 11 years after diagnosis. (C) Small cell lung cancer (SCLC) with faint cytoplasmic OTP staining and absence of nuclear staining. Original magnifications 200x.
Supplementary Figure 2 from The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Authors: Jiang Xiaofeng , Zhou Jun , Giobbie-Hurder Anita , Wargo Jennifer , Hodi F. Stephen
Published: April 2023

PDF file - 177K, PI3K-mTOR-S6 pathway influences PD-L1 expression
Supplementary Figure 4 from CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis
Authors: Fu Tao , Pappou Emmanouil P. , Guzzetta Angela A. , Jeschke Jana , Kwak Ruby , Dave Pujan , Hooker Craig M. , Morgan Richard , Baylin Stephen B. , Iacobuzio-Donahue Christine A. , Wolfgang Christopher L. , Ahuja Nita
Published: April 2023

PDF file, 545K, Kaplan-Meier survival estimates of time-to-recurrence in 99 patients with duodenal adenocarcinomas by (A) age, (B) stage, (C) differentiation, and (D) chemotherapy and/or radiotherapy.
Supplementary Figure 2 from CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis
Authors: Fu Tao , Pappou Emmanouil P. , Guzzetta Angela A. , Jeschke Jana , Kwak Ruby , Dave Pujan , Hooker Craig M. , Morgan Richard , Baylin Stephen B. , Iacobuzio-Donahue Christine A. , Wolfgang Christopher L. , Ahuja Nita
Published: April 2023

PDF file, 342K, Distributions of MSI, CIMP and MLH1 methylation in 99 patients with duodenal adenocarcinomas.
Figure S3A from Identification of Transcriptional Subgroups in EGFR-Mutated and EGFR/KRAS Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated with Patient Outcome
Authors: Planck Maria , Isaksson Sofi , Veerla Srinivas , Staaf Johan
Published: April 2023

Figure S3A - PDF file 6934K, Expression pattern of EGFR-1/2 multicohort centroid genes across included adenocarcinoma cohorts
Figure S2 from Identification of Transcriptional Subgroups in EGFR-Mutated and EGFR/KRAS Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated with Patient Outcome
Authors: Planck Maria , Isaksson Sofi , Veerla Srinivas , Staaf Johan
Published: April 2023

Figure S2 - PDF file 95K, Differences in patterns of copy number gain and loss between EGFR-1/2 and wt/wt-1/2 transcriptional subgroups
Supplementary Figure 2 from The CXCL12–CXCR4 Chemokine Pathway: A Novel Axis Regulates Lymphangiogenesis
Authors: Zhuo Wei , Jia Lin , Song Nan , Lu Xin-an , Ding Yanping , Wang Xiaofeng , Song Xiaomin , Fu Yan , Luo Yongzhang
Published: April 2023

PDF file - 3.9MB, Expression of CXCR4 on lymphatic endothelial cells in vitro and in vivo
Supplementary Figure S3 from Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation
Authors: Martin Eric S. , Belmont Peter J. , Sinnamon Mark J. , Richard Larissa Georgeon , Yuan Jing , Coffee Erin M. , Roper Jatin , Lee Lydia , Heidari Pedram , Lunt Sophia Y. , Goel Gautam , Ji Xiadong , Xie Zhi , Xie Tao , Lamb John , Weinrich Scott L. , VanArsdale Todd , Bronson Roderick T. , Xavier Ramnik J. , Vander Heiden Matthew G. , Kan Julie L. C. , Mahmood Umar , Hung Kenneth E.
Published: April 2023

PDF file - 29 KB, Comparison of metabolic readouts in AP and AKP cell lines
Supplementary Figure 5 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Authors: Cervantes Andres , Elez Elena , Roda Desamparados , Ecsedy Jeffrey , Macarulla Teresa , Venkatakrishnan Karthik , Roselló Susana , Andreu Jordi , Jung JungAh , Sanchis-Garcia Juan Manuel , Piera Adelaida , Blasco Inma , Maños Laura , Pérez-Fidalgo José-Alejandro , Fingert Howard , Baselga Jose , Tabernero Josep
Published: April 2023

PDF file, 2119K, Figure S5. Changes in chromosome alignment and spindle bipolarity on days 1 and 21.
Supplementary Figure 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Authors: Cervantes Andres , Elez Elena , Roda Desamparados , Ecsedy Jeffrey , Macarulla Teresa , Venkatakrishnan Karthik , Roselló Susana , Andreu Jordi , Jung JungAh , Sanchis-Garcia Juan Manuel , Piera Adelaida , Blasco Inma , Maños Laura , Pérez-Fidalgo José-Alejandro , Fingert Howard , Baselga Jose , Tabernero Josep
Published: April 2023

PDF file, 1749K, Figure S4. Changes in tumor mitotic index on days 1, 7, and 21.
Supplementary Figure 7 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia
Authors: Sánchez-Sánchez Beatriz , Gutiérrez-Herrero Sara , López-Ruano Guillermo , Prieto-Bermejo Rodrigo , Romo-González Marta , Llanillo Marcial , Pandiella Atanasio , Guerrero Carmen , Miguel Jesús F. San , Sánchez-Guijo Fermín , del Cañizo Consuelo , Hernández-Hernández Angel
Published: April 2023

PDF file - 28KB, Supplementary figure 7. Downregulation of multiple NADPH oxidases in K562 cells.
Supplementary Figure 6 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia
Authors: Sánchez-Sánchez Beatriz , Gutiérrez-Herrero Sara , López-Ruano Guillermo , Prieto-Bermejo Rodrigo , Romo-González Marta , Llanillo Marcial , Pandiella Atanasio , Guerrero Carmen , Miguel Jesús F. San , Sánchez-Guijo Fermín , del Cañizo Consuelo , Hernández-Hernández Angel
Published: April 2023

PDF file - 44KB, Supplementary figure 6. Validation of the oligonucleotides pairs used to detect the expression of the different isoforms of NADPH oxidases.
Supplementary Figure 3 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia
Authors: Sánchez-Sánchez Beatriz , Gutiérrez-Herrero Sara , López-Ruano Guillermo , Prieto-Bermejo Rodrigo , Romo-González Marta , Llanillo Marcial , Pandiella Atanasio , Guerrero Carmen , Miguel Jesús F. San , Sánchez-Guijo Fermín , del Cañizo Consuelo , Hernández-Hernández Angel
Published: April 2023

PDF file - 44KB, Supplementary figure 3. Antioxidants and rotenone treatment hamper K562 cell proliferation. DPI treatment reduces BCR-ABL protein levels.
Supplementary Figure 1 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia
Authors: Sánchez-Sánchez Beatriz , Gutiérrez-Herrero Sara , López-Ruano Guillermo , Prieto-Bermejo Rodrigo , Romo-González Marta , Llanillo Marcial , Pandiella Atanasio , Guerrero Carmen , Miguel Jesús F. San , Sánchez-Guijo Fermín , del Cañizo Consuelo , Hernández-Hernández Angel
Published: April 2023

PDF file - 68KB, Supplementary Figure 1. Inhibitors of NADPH oxidases and BCR-ABL synergize to avoid the proliferation of two different CML cell lines.
Supplementary Table 1 from A Targeted RNAi Screen of the Breast Cancer Genome Identifies KIF14 and TLN1 as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast Cancer
Authors: Singel Stina Mui , Cornelius Crystal , Batten Kimberly , Fasciani Gail , Wright Woodring E. , Lum Lawrence , Shay Jerry W.
Published: April 2023

PDF File - 852K, Annotation of all shRNA clones used in the current study from Open Biosystems (Lafayette, CO) CSHL Hs shRNAmir 6.13 library.
Supplementary Tables 1 - 3 from Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
Authors: Yu Ziyang , Chen Sen , Sowalsky Adam G. , Voznesensky Olga S. , Mostaghel Elahe A. , Nelson Peter S. , Cai Changmeng , Balk Steven P.
Published: April 2023

PDF file - 97KB, Supplementary Table 1. List of genes up-regulated in abiraterone-resistant VCaP xenograft samples. Supplementary Table 2. List of genes down-regulated in abiraterone-resistant VCaP xenograft samples. Supplementary Table 3. AR mutation detected in RNA-Seq analysis.
Supplementary Table 2 from Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Authors: Schott Anne F. , Landis Melissa D. , Dontu Gabriela , Griffith Kent A. , Layman Rachel M. , Krop Ian , Paskett Lacey A. , Wong Helen , Dobrolecki Lacey E. , Lewis Michael T. , Froehlich Amber M. , Paranilam Jaya , Hayes Daniel F. , Wicha Max S. , Chang Jenny C.
Published: April 2023

PDF file - 39K, Probability of DLT. This table estimates the probability of dose-limiting toxicity by dose level
Figures S4 & S5 from Adrenomedullin Blockade Suppresses Growth of Human Hormone–Independent Prostate Tumor Xenograft in Mice
Authors: Berenguer-Daizé Caroline , Boudouresque Françoise , Bastide Cyrille , Tounsi Asma , Benyahia Zohra , Acunzo Julie , Dussault Nadège , Delfino Christine , Baeza Nathalie , Daniel Laurent , Cayol Mylène , Rossi Dominique , El Battari Assou , Bertin Denis , Mabrouk Kamel , Martin Pierre-Marie , Ouafik L'Houcine
Published: April 2023

PDF file 97K, AM induced activation of MAPK pathway and Normal Vascularization is not disrupted by {alpha}AM treatment
Supplementary Figures from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Authors: Shimamura Takeshi , Chen Zhao , Soucheray Margaret , Carretero Julian , Kikuchi Eiki , Tchaicha Jeremy H. , Gao Yandi , Cheng Katherine A. , Cohoon Travis J. , Qi Jun , Akbay Esra , Kimmelman Alec C. , Kung Andrew L. , Bradner James E. , Wong Kwok-Kin
Published: April 2023

Supplementary Figures - PDF file 770K, Supplementary Figure 1. JQ1 treatment induces apoptosis proliferation arrest in a subset of NSCLC cells Supplementary Figure 2. JQ1 treatment promotes a depletion of 57kDa MYC in a time dependent manner in NSCLC cells Supplementary Figure 3. FOSL1 depletion is induced by JQ1 treatment regardless of the status of LKB1 Supplementary Figure 4. JQ1 treatment in mutant kras mouse induce apoptosis
Supplementary Figure 5 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
Authors: Dal Pra Alan , Lalonde Emilie , Sykes Jenna , Warde Fiona , Ishkanian Adrian , Meng Alice , Maloff Chad , Srigley John , Joshua Anthony M. , Petrovics Gyorgy , van der Kwast Theodorus , Evans Andrew , Milosevic Michael , Saad Fred , Collins Colin , Squire Jeremy , Lam Wan , Bismar Tarek A. , Boutros Paul C. , Bristow Robert G.
Published: April 2023

Supplementary Figure 5 - PDF file 61K, Univariate Kaplan-Meier plots of biochemical relapse-free survival in a subgroup of patients treated without androgen deprivation therapy (ADT) in the (A) aCGH- and (B) IHC-cohorts
Supplementary Figure 1 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
Authors: Dal Pra Alan , Lalonde Emilie , Sykes Jenna , Warde Fiona , Ishkanian Adrian , Meng Alice , Maloff Chad , Srigley John , Joshua Anthony M. , Petrovics Gyorgy , van der Kwast Theodorus , Evans Andrew , Milosevic Michael , Saad Fred , Collins Colin , Squire Jeremy , Lam Wan , Bismar Tarek A. , Boutros Paul C. , Bristow Robert G.
Published: April 2023

Supplementary Figure 1 - PDF file 49K, Schematic representation of TMPRSS2-ERG fusion allele in the chromosome 21q22.2/21q22.3. Gene positions are based on NCBI36/hg18 human genome reference
Supplementary Table 1 from Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer
Authors: Martens-de Kemp Sanne R. , Nagel Remco , Stigter-van Walsum Marijke , van der Meulen Ida H. , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file - 24K, The genome-wide siRNA screen in SW1573 revealed 293 siRNAs that caused a significant decrease in cell viability.
Supplementary Figure 4 from Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer
Authors: Martens-de Kemp Sanne R. , Nagel Remco , Stigter-van Walsum Marijke , van der Meulen Ida H. , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file - 75K, Deconvolution of AURKB and AURKC siRNA pools in multiple tumor cell lines and the effect of simultaneous knockdown of the aurora kinase genes on cell viability.
Supplementary Figure 1 from Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma
Authors: Jones Kimberley , Vari Frank , Keane Colm , Crooks Pauline , Nourse Jamie P. , Seymour Louise A. , Gottlieb David , Ritchie David , Gill Devinder , Gandhi Maher K.
Published: April 2023

PDF file - 36K, Sensitivity and specificity of sCD163 and sTARC as biomarkers in cHL. (A-D) Receiver Operating Characteristic (ROC) plots demonstrate high sensitivity and specificity of (A) sCD163 pre-therapy cHL versus healthy participant; (B) sCD163 pre-therapy cHL versus CR six months post-therapy; (C) sTARC pre-therapy cHL versus healthy participants; (D) sTARC pre-therapy cHL versus CR six months post-therapy. AUC, area under the curve.
Supplementary Figure 5 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets
Authors: Stefanska Barbara , Cheishvili David , Suderman Matthew , Arakelian Ani , Huang Jian , Hallett Michael , Han Ze-Guang , Al-Mahtab Mamun , Akbar Sheikh Mohammad Fazle , Khan Wasif Ali , Raqib Rubhana , Tanvir Imrana , Khan Haseeb Ahmed , Rabbani Shafaat A. , Szyf Moshe
Published: April 2023

PDF file - 1284KB, Supplementary Figure S5. Effects of stable RASAL2 (A-D) or NENF (E-H) depletion on cell viability (A,E) and anchorage independent growth (B,F, soft agar assay) in HepG2, SkHep1, and NorHep. Three different shRNA sequences targeting NENF and six different shRNA sequences targeting RASAL2 were used that were limited to two shRNA sequences for each gene (shRASAL2-7 and sh-RASAL2-9, shNENF-2 and shNENF-1) that produced the best knockdown by lentiviral transduction. Expression of RASAL2 (C,D) and NENF (G,H) on mRNA and protein levels was measured, respectively, by QPCR after 10 days and by western blot after 14 days post-lentiviral transduction. Expression on mRNA is expressed as a percentage of control relative to GAPDH. For cell viability assay, control cells (sh-Scr, transduced with lentivirus expressing non-targeting RNA) and cells with stable depletion of the target genes were seeded at a density of 3-6 x 105 per a 10-cm tissue culture dish, counted and split every three days up to day 9 (schedule of transient transfection). All results represent mean � S.D. of at least three determinations - ***P < 0.001, **P < 0.01, *P < 0.05.